Abstract:A novel formulation containing polyvinylpyrrolidone (PVP) K-30-coated norcantharidin (NCTD) chitosan nanoparticles (PVP-NCTD-NPs) was prepared by ionic gelation between chitosan and sodium tripolyphosphate. The average particle size of the PVP-NCTD-NPs produced was 140.03 +/- 6.23 nm; entrapment efficiency was 56.33% +/- 1.41%; and drug-loading efficiency was 8.38% +/- 0.56%. The surface morphology of NCTD nanoparticles (NPs) coated with PVP K 30 was characterized using various analytical techniques, including X-ray diffraction and atomic force microscopy. NCTD and its metabolites were analyzed using a sensitive and specific liquid chromatography-tandem mass spectrometry method with samples from mice and rats. The results indicated the importance of the PVP coating in controlling the shape and improving the entrapment efficiency of the NPs. Pharmacokinetic profiles of the NCTD group and PVP-NCTD-NP group, after oral and intravenous administration in rats, revealed that relative bioavailabilities were 173.3% and 325.5%, respectively. The elimination half-life increased, and there was an obvious decrease in clearance. The tissue distribution of NCTD in mice after the intravenous administration of both formulations was investigated. The drug was not quantifiable at 6 hours in all tissues except for the liver and kidneys. The distribution of the drug in the liver and bile was notably improved in the PVP-NCTD-NP group. The metabolites and excretion properties of NCTD were investigated by analyzing rat feces and urine samples, collected after oral administration. A prototype drug and two metabolites were found in the feces, and seven metabolites in the urine. The primary elimination route of NCTD was via the urine. The quantity of the parent drug eliminated in the feces of the PVP-NCTD-NP group, was 32 times greater than that of the NCTD group, indicating that the NPs dramatically increased the reduction quantity from liver to bile. We conclude that PVP-NCTD-NPs are an adequate formulation for enhancing the absorption of NCTD, and significantly improving therapeutic effects targeting the hepatic system. Decarboxylation and hydroxylation were the dominant metabolic pathways for NCTD. Metabolites were mainly excreted into rat kidney and finally into urine.

Study on Pharmacokinetic Profile of PVP-coated Norcantharidin-Chitosan Nanoparticles in Rats by HPLC-MS/MS

Pharmacokinetics, Tissue Distribution, and Metabolites of a Polyvinylpyrrolidone-Coated Norcantharidin Chitosan Nanoparticle Formulation in Rats and Mice, Using LC-MS/MS

Study on the Physicochemical Properties and the Intestinal Absorption Kinetics of Norcantharidin in Rats

Novel Norcantharidin-Loaded Liver Targeting Chitosan Nanoparticles to Enhance Intestinal Absorption

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Preparation and In Vitro and In Vivo Evaluation Of Panax Notoginseng Saponins-loaded Nanoparticles Coated with Trimethyl Chitosan Derivatives

Study on Pharmacokinetics and Bioavailability of Nimodipine Nanostructured Lipid Carrier in Rats

Studies on Anti-Hepatocarcinoma Effect, Pharmacokinetics and Tissue Distribution of Carboxymethyl Chitosan Based Norcantharidin Conjugates.

Determination of Norcantharidin in Mouse Tissues by Liquid Chromatography Coupled to Tandem Mass Spectrometry and its Tissue Distribution Study

Norcantharidin-Associated Galactosylated Chitosan Nanoparticles For Hepatocyte-Targeted Delivery

Liquid chromatography–tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice

Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.

Liposomal Nanodrug Based on Norcantharidin Derivative for Increased in Vivo Activity

Two modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticles

Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity

Preparation, Characterization and Pharmacokinetics of 10-Hydroxy-camptothecin Nanosuspension

Chitosan-modified mesoporous silica nanoparticles for the oral delivery of Norcantharidin: In vitro and in vivo assessment

A UPLC-MS/MS Method for Simultaneous Determination of Six Bioactive Compounds in Rat Plasma, and its Application to Pharmacokinetic Studies of Naoshuantong Granule in Rats

Pharmacokinetics and Biodistribution of Surface Modification Polymeric Nanoparticles

Quantification of CPT13 in rat plasma using LC–MS/MS for a pharmacokinetic study

Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin